Viridian Therapeutics (VRDN)
(Delayed Data from NSDQ)
$16.87 USD
-0.54 (-3.10%)
Updated Aug 4, 2025 03:59 PM ET
After-Market: $16.87 0.00 (0.00%) 4:46 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Viridian Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
VRDN 16.87 -0.54(-3.10%)
Will VRDN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRDN
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?
VRDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
MannKind (MNKD) Matches Q3 Earnings Estimates
Other News for VRDN
Viridian Therapeutics Announces Inducement Grants for New Employees | VRDN stock news
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VRDN ...
Viridian partners with Japanese firm for Veligrotug and VRDN-003
Viridian Therapeutics (VRDN) Partners with Kissei for Japanese Market Expansion
Viridian enters veligrotug, VRDN-003 collaboration and license pact with Kissei